128270-60-0 Bivalirudin Bivalirudin Price
We promise our customer following items
1.Reasonable price:
2.Low moq:No worry about the low moq, our moq is 1 gram or lower.
3.Good and efficient service,Fast Delivery
4.Super-good quality
Prouduct name: Bivalirudin
CAS: 148031-34-9
Appearance: White or light white power
Purity: 98%min
Certification of High quality 128270-60-0 with best price
Appearance |
White powder |
HPLC Purity, % |
≥98.0% |
Essential information of High quality 128270-60-0 with best price
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin.It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.
More information of High quality 128270-60-0 with best price
Storage:It should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.
Application of High quality 128270-60-0 with best price
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI. Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
CAS NO:30123-17-2
CAS NO:171596-29-5
CAS NO:171596-29-5
CAS NO:171596-29-5
CAS NO:171596-29-5
CAS NO:171596-29-5
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View